Artisan, Singapore’s A-Bio Join Forces On Recombinant Sepsis Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Massachusetts firm is first-of-a-kind venture capital-funded, Japanese spinoff to focus on a top-priority compound, Artisan CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
AKP Takes Over Artisan To Progress ART-123
Japan's Asahi Kasei Pharma announced Nov. 22 that its acquisition of Massachusetts-based Artisan Pharma, a company it spun out in 2006.
Singapore Biomedical Sciences Group Director Yeoh Keat Chuan: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Singapore government official talks about the country’s R&D strengths and how it is handling increased competition from other Asian nations.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.